Editorial Staff

Transparency, Please! MBTA Resists Disclosure of Arbitration Award

/in , , /by Editorial Staff
Share on Facebook
Share on Twitter
Share on
LinkedIn
+

Joe Selvaggi talks with attorney for Pioneer Public Interest Law Center (PPILC) John La Liberte, about the work he did to successfully gain access to the MBTA retirement fund’s arbitration agreement after a seven-month legal struggle.

Follow on Apple Follow on Spotify Follow on Stitcher

Guest:

John La Liberte has been a litigator at a prestigious Boston boutique firm for over 30 years where he has also served as the firm’s general counsel. John
decided that he wanted to join Pioneer Public Interest Law Center to do what he hoped to do when he went to law school — engage in impact litigation.
WATCH:

Recent Episodes

U.S. Manufacturing Health: Does the U.S. Need an Industrial Policy?

Scott Lincicome from the Cato Institute discusses the U.S. manufacturing industry, international trade, and industrial policy. He dispels the myth of manufacturing decline, highlighting sector evolution and productivity. The conversation moves to industrial policy, emphasizing the need for targeted protection and cautioning against broad subsidization due to potential inefficiencies.

Challenging Government Prerogatives: SCOTUS Reconsiders Deference to Executive Agencies

Joe Selvaggi engages in a conversation with legal scholar Ilya Shapiro from the Manhattan Institute regarding the Loper Bright Enterprises Supreme Court case that questions the Chevron Doctrine. This doctrine instructs judges to defer to government agencies in situations where laws are silent or unclear.

Harvard’s Sullied Halo: Journalists Teach Lesson on Plagiarism

Joe Selvaggi talks with investigative reporter Chris Brunet about his role investigating and exposing former Harvard President Claudine Gay’s academic plagiarism, a story that lead to her eventual resignation.

Drug Discount Distortions: How Middlemen Increase Costs and Reduce Access

Joe Selvaggi talks with Drs. Bill Smith and Robert Popovian about how the complex system of rebates from drug companies to insurance firms serve to increase costs and reduce access for patients.